

# OH'S INTENSIVE CARE MANUAL

---

# OH'S INTENSIVE CARE MANUAL

NINTH EDITION

---

## ***Editors***

**Jonathan M. Handy** BSc, MBBS, FRCA, EDIC, FFICM, RCPPathME

Consultant of Intensive Care Medicine and Anaesthesia  
Royal Marsden Hospital;  
Honorary Senior Lecturer  
Imperial College London  
London, United Kingdom

**Bala Venkatesh** MBBS, MD(Int.Med), FRCA, FFARCSI, MD(UK),  
FCICM, FAHMS

**Academic Professor**, Gold Coast University Hospital  
**Program Director**, Critical Care, The George Institute for Global Health  
**Professor** of Intensive Care, University of QLD  
**Honorary Professor**, University of New South Wales

## ***Associate Editors***

**Jeremy Cohen** BSc, MBBS, MRCP, FRCA, FCICM, PhD

Associate Professor, Intensive Care, Wesley Hospital, Brisbane, QLD  
Associate Professor, Intensive Care, Royal Brisbane and Women's Hospital, Brisbane, QLD  
Honorary Professorial Fellow, The George Institute for Global Health  
Adjunct Associate Professor, University of New South Wales

**Daniel Martin** OBE, BSc, MBChB, FRCA, FFICM, PhD

Professor of Perioperative and Intensive Care Medicine  
Peninsula Medical School, University of Plymouth  
Plymouth, Devon, United Kingdom  
Consultant of Intensive Care Medicine, University Hospitals Plymouth, Devon, United Kingdom



Copyright © 2026, Elsevier Inc. All rights reserved. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

For accessibility purposes, images in electronic versions of this book are accompanied by alt-text descriptions provided by Elsevier. For more information, see <https://www.elsevier.com/about/accessibility>.

Books and Journals published by Elsevier comply with applicable product safety requirements. For any product safety concerns or queries, please contact our authorised representative, Elsevier B.V., at [productsafety@elsevier.com](mailto:productsafety@elsevier.com)

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

Previous editions copyrighted 2019, 2014, 2009, 2003, 1991, 1990, 1985, and 1979.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

#### Notice

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN 978-0-443116117

Printed in India

Last digit is the print number: 9 8 7 6 5 4 3 2 1

*Executive Content Strategist:* Charlotta Kryhl

*Content Development Specialist:* Teddy Lewis

*Project Manager:* Nandhini Thanga Alagu

*Design:* Patrick Ferguson

*Marketing Manager:* Mary McCabe-Dunn



Working together  
to grow libraries in  
developing countries

[www.elsevier.com](http://www.elsevier.com) • [www.bookaid.org](http://www.bookaid.org)

# Contents

List of Contributors	v
Preface	xvii
Acknowledgements	xviii

## Part One - Structure and Process

1	Design and organisation of intensive care units	3
	<i>Peter Kruger, Nhi Nguyen</i>	
2	Rapid response systems: care of critically ill patients outside of critical care	10
	<i>John Robert Welch, Christian Peter Subbe</i>	
3	Critical care nursing	16
	<i>John Robert Welch</i>	
4	Allied health professionals in ICU	24
	<i>Ella Terblanche, Jackie McRae, Sarah Dzumbira, Paul Twose</i>	
5	Team-based healthcare delivery	30
	<i>Laura Vincent, Gerry O'Callaghan</i>	
6	Pandemic and major incident planning	41
	<i>James O'Carroll, S. Ramani Moonesinghe</i>	
7	Transport of critically ill patients	48
	<i>Roy Fischer, Krista Mos</i>	
8	Common problems after ICU	60
	<i>Andrew Slack, Kate Tantom, Joel Meyer</i>	

## Part Two - Decision Making

9	Clinical assessment of the critically ill patient	69
	<i>Jeremy Cohen, Mary Pinder, Bala Venkatesh</i>	
10	Severity scoring and outcome prediction	75
	<i>C Jake Barlow, David Pilcher</i>	
11	Trials	89
	<i>Simon Finfer, Lennie P.G. Derde, Naomi E. Hammond, Anthony Delaney</i>	

- 12 **Ethics** 99  
*Victoria Metaxa*
- 13 **Treatment limitation and palliative care** 103  
*Sarah Cox, Phoebe Wright*
- 14 **The determination of death in ICU** 109  
*Ian Thomas, Stewart Moodie*

### Part Three - Sepsis and Infections Requiring ICU Support

- 15 **Sepsis and septic shock** 119  
*Jonathan Edward Millar, Manu Shankar-Hari*
- 16 **Multi-organ dysfunction syndrome** 127  
*Matthew J. Maiden, Sarah C. Sasson*
- 17 **Genetics in sepsis** 137  
*Jeremy Cohen, David Evans, Bala Venkatesh*
- 18 **Healthcare-associated infection** 144  
*Stuart Dickson*
- 19 **Fungal infection** 151  
*Alastair Craig Carr*
- 20 **Principles of antimicrobial use in the intensive care unit** 162  
*Marta Ulldemolins, Jason A. Roberts, Jeffrey Lipman*
- 21 **Tropical infections** 169  
*Binila Chacko I, Sarah Elizabeth Crawford Platt, Steven Tong, Duong Ha Thi Hai, Bharath Kumar Tirupakuzhi Vijayaraghavan*
- 22 **Severe soft-tissue infections** 182  
*Paul B. Bartley, Carl Joseph Lisec*

### Part Four - Cardiovascular Intensive Care

- 23 **Overview of shock** 191  
*Matthew J. Maiden, Emily J. See, Sandra L. Peake*
- 24 **Haemodynamic monitoring** 198  
*Denzil Gill, Christopher Peter Nickson, Kevin Pathmanathan, Sarah Wesley*
- 25 **Echocardiography in intensive care** 219  
*James Richards Anstey, Craig George Terrell Morris, Ubbo F. Wiersema*
- 26 **Inotropes and vasopressors (vasoactive drugs)** 232  
*Adam M. Deane, Ashish K. Khanna, John Myburgh*

- 27 Vasodilators and antihypertensives 241  
*David O'Callaghan, David Benjamin Antcliffe*
- 28 Mechanical cardiac supports 253  
*Vince Pellegrino, Julia Coull, Brooke Riley*
- 29 Acute coronary syndromes, investigations and interventions 263  
*Shanthosh Sivapathan, Faraz Pathan, Ian Seppelt*
- 30 Cardiopulmonary resuscitation (including defibrillation) 289  
*Peter Thomas Morley, Jerry P. Nolan*
- 31 Cardiac arrhythmias 298  
*Andrew Holt, Russell David Laver*
- 32 Cardiac pacing 366  
*Francisca Caetano, Brijesh Vipinchandra Patel*
- 33 Acute heart failure and pulmonary hypertension 378  
*Daniel Taylor, Nicholas Ioannou*
- 34 Valvular and congenital heart disease and infective endocarditis 398  
*Steven Galluccio, Lisa-Marie Pereira*
- 35 Acute aortic syndrome 415  
*Clare Quarterman*

## Part Five - Respiratory Failure

- 36 Overview of respiratory failure in ICU 433  
*Shailesh Bihari, Andrew Bersten*
- 37 Acute respiratory distress syndrome 442  
*Andrew Bersten, Shailesh Bihari*
- 38 Respiratory monitoring 455  
*Andrew Bersten, Thomas J. Morgan*
- 39 Troubleshooting mechanical ventilation waveforms 473  
*David V. Tuxen, Paul Nixon*
- 40 Chest imaging and ultrasound in the ICU 483  
*Bhavin Rawal, Ubbo F. Wiersema*
- 41 Oxygen therapy, humidifiers and inhalation therapy 502  
*Shailesh Bihari, Steven Galluccio, Andrew Bersten*
- 42 Mechanical ventilator support 518  
*Andrew Bersten, Shailesh Bihari*
- 43 Non-invasive ventilation 533  
*Graeme Duke, Andrew Bersten*

- 44 **Airway management and acute airway obstruction** 540  
*Gordon YS Choi, Gavin Matthew Joynt*
- 45 **Pulmonary embolism** 554  
*Aimee Brame, Brijesh Vipinchandra Patel*
- 46 **Acute severe asthma** 564  
*David V. Tuxen, Mark Hew, Eve Denton*
- 47 **Acute respiratory failure in chronic obstructive pulmonary disease** 578  
*Matthew T. Naughton, David V. Tuxen*
- 48 **Pneumonia** 589  
*Wai Tat WONG, Eunise WS Ho, Lowell Ling*
- 49 **COVID-19** 605  
*Hugh Montgomery, Simon Stallworthy, Sampath Weerakkody*
- 50 **Extracorporeal membrane oxygenation for respiratory failure** 614  
*Vince Pellegrino, Brooke Riley, Julia Coull*

## Part Six - Gastroenterological Emergencies and Surgery

- 51 **Enteral and parenteral nutrition** 623  
*Yasmine Ali Abdelhamid, Marianne Chapman, Adam M. Deane*
- 52 **Acute gastrointestinal bleeding** 630  
*Sheng Qiu, Constantinos Simillis, Shahnawaz Rasheed*
- 53 **Acute pancreatitis** 642  
*Aimee Brame*
- 54 **Hepatic failure** 648  
*Freya Glover, Rohit Saha, Brian J. Hogan*

## Part Seven - Acute Renal Failure

- 55 **Acute kidney injury** 671  
*Emily J. See, Rinaldo Bellomo*
- 56 **Renal replacement therapy** 677  
*Emily J. See, Rinaldo Bellomo*
- 57 **Acid-base disorders and hyperlactataemia** 684  
*David Story, Thomas J. Morgan, David J. Cooper*
- 58 **Fluid and electrolyte therapy** 696  
*Anthony Delaney, Priya Nair, Naomi E. Hammond, Simon Finfer, John Myburgh*

**Part Eight - Neurological Disorders**

- 59 Disorders of consciousness 715  
*Xiuxian Pham, Toby Jeffcote, Andrew Udy*
- 60 Cerebral protection 729  
*Colin Andrew Eynon*
- 61 Status epilepticus 736  
*Lara Prisco, Mario Ganau, Arjune Sen*
- 62 Acute cerebrovascular complications 749  
*Thearina de Beer*
- 63 Meningitis and encephalomyelitis 761  
*Michel Toledano, Nicholas WS Davies*
- 64 Neuromonitoring 772  
*Toby Jeffcote, Xiuxian Pham, Andrew Udy*
- 65 Delirium 783  
*Edward John Richard Watson, Michael Charles Reade, Marcela Paola Vizcaychipi*
- 66 ICU-acquired weakness 790  
*Zudin Puthuchear, Carol L. Hodgson*
- 67 Neuromuscular disorders 801  
*Manoj Krishan Saxena, Walid Matar*

**Part Nine - Endocrine Disorders**

- 68 Diabetic emergencies and glucose control in the ICU 815  
*Mahesh Ramanan, Elif Ekinci*
- 69 Polyuria in the ICU – diabetes insipidus and other causes 824  
*Alastair Craig Carr*
- 70 Thyroid emergencies 838  
*Alex Li, Jonathan M. Handy*
- 71 Adrenocortical insufficiency in critical illness 847  
*Jeremy Cohen, Bala Venkatesh*

**Part Ten - Surgical Patient**

- 72 Preoperative assessment of the high-risk patient 857  
*James Francis Waiting, Mevan Gooneratne, Don Milliken*
- 73 Postoperative cardiac intensive care 862  
*Nick Fletcher, Carlos Corredor*



- 74 Post-operative thoracic surgical patient 872  
*Katrina Bramley*
- 75 Management of the post-operative neurosurgical patient 879  
*Judith Bellapart, Rosalind L. Jeffree, Alan Coulthard*
- 76 Postoperative care after major abdominal operations 885  
*Janet Liang, Ywain Thomas Lawrey*

## Part Eleven - Severe and Multiple Trauma

- 77 Severe and multiple injuries 899  
*Rebecca Schroll, Li C. Hsee*
- 78 Severe head injuries 908  
*Mark Howard Wilson*
- 79 Maxillofacial and upper-airway injuries 915  
*Jason Pincus, Alexander M. Bobinskas, Scott Charles Borgna*
- 80 Chest injuries 922  
*Christopher Tobias Edmunds, Sarah McNeilly, Ubbo F. Wiersema*
- 81 Spinal injuries 933  
*Oliver James Flower, Sumesh Arora*
- 82 Abdominal and pelvic injuries 946  
*Sarah McNeilly*

## Part Twelve - Special Populations

- 83 Intensive care and the elderly 957  
*Linsey Emma Christie, Richard T. Keays*
- 84 Obesity 967  
*Rob Bevan*
- 85 The immunocompromised host 975  
*Alex Padiglione, Steven A. McGloughlin*
- 86 Implications of solid tumours for intensive care 982  
*Timothy Wigmore, Pascale Gruber, Sef Carter*
- 87 Māori, Aboriginal and Torres Strait Islander populations and critical illness: an overview 989  
*Paul Secombe, Alex Brown, Alex Browne*
- 88 Pre-eclampsia, eclampsia and related disorders in pregnancy 997  
*Sadie Callahan, Josephine Gwyneth Laurie, Nai An Lai*
- 89 Obstetric emergencies 1008  
*Loki Bjorn Johnk, Josephine Gwyneth Laurie, Nai An Lai*

**Part Thirteen - The Paediatric Patient**

- 90    **The critically ill child**    1021  
*Andrew J. Jones*
- 91    **Upper airway obstruction in children**    1027  
*Paul James, Michelle Alisio*
- 92    **Acute respiratory distress in children**    1035  
*Tavey Dorofaeff, Mark Graeme Coulthard*
- 93    **Paediatric fluid and electrolyte therapy**    1045  
*Sophie Skellett*
- 94    **Sedation and analgesia in children**    1056  
*Andy Petros*
- 95    **Shock and cardiac disease in children**    1066  
*Charles Larson*
- 96    **Neurological emergencies in children**    1080  
*Nitesh Singhal, Michaela Waak*
- 97    **Paediatric trauma**    1095  
*Kevin McCaffery*
- 98    **Paediatric treatment limitation and organ donation**    1102  
*Sainath Raman, Helen Miles, Tina Anne Coco*
- 99    **Paediatric poisoning and envenomation**    1109  
*Sainath Raman, Angela Burgett, Carol J. Wylie*
- 100    **Paediatric cardiopulmonary resuscitation**    1119  
*Andrea S. Christoff, Gabrielle A. Nuthall*

**Part Fourteen - Environmental Injuries**

- 101    **Poisoning and drug intoxication**    1129  
*Tamishta Hensman, Brendan R. Murfin, Nicholas A. Barrett*
- 102    **Submersion**    1142  
*Andrew Semark, Alice Young, James P. McCullough*
- 103    **Burns**    1146  
*Edward John Richard Watson, Marcela Paola Vizcaychipi*
- 104    **Thermal disorders**    1153  
*Stephen William Lam, Lisa-Marie Pereira, Richard Strickland*
- 105    **Electrical safety and injuries**    1168  
*Christina HY So, Christopher Pak-to Lee, Po Tong Chui*
- 106    **Envenomation**    1180  
*Catherine L. Tacon, Mark Little, Christopher Peter Nickson*

**107**    **Blast and ballistic trauma**    1191  
*Michael Charles Reade, Tom Woolley, Elissa Mary Milford*

**108**    **Chemical, biological, radiological and nuclear exposure management**    1204  
*Andrew McDonald Johnston, Sophia L. De Maria*

### Part Fifteen - Inflammatory and Immune Disorders

**109**    **Anaphylaxis**    1217  
*Peter Rostron Platt, Paul Harold Martin Sadleir*

**110**    **Therapeutic plasma exchange and intravenous immunoglobulin therapy**    1228  
*Alpesh Patel, Shailesh Bihari*

**111**    **Rheumatology**    1239  
*Tamir Malley, Animesh Singh, Richard Stratton*

### Part Sixteen - Haematological Management

**112**    **Blood transfusion and patient blood management**    1253  
*Craig French, Zoe McQuilten, James Winearls*

**113**    **Haemostatic failure**    1267  
*James Winearls, Zoe McQuilten, Charithani Bhagya Keragala*

**114**    **Haematological malignancy**    1286  
*Pascale Gruber, Timothy Wigmore, Sef Carter*

### Part Seventeen - Transplantation

**115**    **Organ donation**    1299  
*Helen Ingrid Opdam, Daniel John Robertson Harvey*

**116**    **Liver and kidney transplantation**    1310  
*Sujit Kumar Mukherjee, Brian J. Hogan, Andrew Slack, Chris Callaghan*

**117**    **Heart transplantation**    1327  
*Priya Nair, Paul Jansz, Peter Macdonald*

**118**    **Lung transplantation**    1336  
*Priya Nair, Stephen Morgan, Paul Jansz, Marshall Plit*

### Part Eighteen - Pharmacologic Considerations

**119**    **Pharmacokinetics, pharmacodynamics and drug monitoring in acute illness**    1349  
*Christine Chung, Jason A. Roberts*

**120**    **Sedation and pain management in intensive care**    1356  
*Luke Torre, Elizabeth T. Tran*

**Index**    1367




Fig. 32.6 Posteroanterior (A) and lateral (B) chest radiographs, with a line that diagrams the expected course of a right ventricular apical pacemaker lead. (Reproduced with permission from Belvin D, Hirschl D, Jain VR, et al. Chest radiographs are valuable in demonstrating clinically significant pacemaker complications that require reoperation. Can Assoc Radiol J. 2011;62(4):290, Figure 1. Copyright Elsevier.)

that will need long-term temporary transvenous pacing (e.g. due to concomitant infection), an active-fixation lead inserted through the skin and connected to an external pacemaker should be considered (the so-called 'temporary-permanent system' or 'externalised pacemaker')<sup>38</sup> (Fig. 32.7). After a short period of observation, the patient can be mobile and lead displacement and threshold rise are rare, meaning the need for the lead repositioning is also rare. The device can be reprogrammed just like any other permanent pacemaker, and the percentage of time that the patient is pacing, or detection of intermittent arrhythmias, can be recorded so where appropriate, a decision to permanently pace or provide other treatment can be made. If the patient does not need a permanent system, removal of the temporary-permanent system is straightforward.

### TESTING THE PACING LEADS

Modern external pacing boxes are available (Fig. 32.8) that will pace in all modes. These units are small, easy to use and can fit into a small pouch suitable for mobile patients. Furthermore, they can perform checks of pacing threshold and sensing.

1. **Pacing threshold:** It is the minimum energy required to be delivered by the pacing system to achieve electrical capture.
  - Set the pacemaker rate at least 10 beats per minute (bpm) faster than the intrinsic heart rate, or at 60 bpm if the patient has a profound bradycardia.

- Set the pacing output at 5 V.
- Confirm ventricular capture (pacing spike immediately followed by a broad QRS at the same rate as that set on the box).
- Decrease the output slowly until capture is lost (pacing spike no longer followed by a broad QRS). This is the pacing threshold and ideally should be less than 1 V.
- Set the output to three times the pacing threshold to allow sufficient safety margin, or at least 3 V.

In those with no underlying rhythm or profound bradycardia, loss of capture will lead to asystole – in which case the output should be rapidly increased until capture returns.


### 2. Pacing sensitivity/sensing

Sensitivity, or sensing, refers to the amplitude of the sensed electrograms. Large electrograms are easy to sense and small ones are not and undersensing may occur.

- Set the pacemaker rate at least 10 bpm slower than the intrinsic heart rate (not possible if extremely slow underlying rhythm or asystole).
- Set the pacing sensitivity at 1mV and the pacing output to the lowest to avoid pacing on the T wave.
- Confirm ventricular sensing (flashing light on the pacing box and no spikes should be seen).
- Increase the sensitivity number (>1 mV) until you see a pacing spike/failure of sensing. This represents the sensitivity threshold of the sensed electrograms.



**Fig. 32.7** Active-fixation lead is connected to a reusable generator secured to the skin with a large occlusive dressing to maintain sterility (A). Chest radiography showing the position of the pacing lead. The active-fixation screw mechanism and the CoreValve are visible (B). (Reproduced with permission from Cuisset T, Quilici J. Subclavicular screwed wire transient pacing to increase safety of transcatheter aortic valve implantation with the CoreValve system. *J Cardiol Cases*. 2011;3(3):e168, [Figures 1 and 2](#).)



**Fig. 32.8** Temporary pacing systems. Medtronic, Inc. (i) Model 5388 (dual-chamber); (ii) model 5348 (single-chamber).

- Set the sensitivity to a half to a third of the sensitivity threshold, to allow continuous sensing of all intrinsic signals (e.g. if it senses at 8 mV, set it at 4 mV or less).
- Do not forget to increase the pacing output.

### PACEMAKER PROGRAMMING

Multiple parameters can be programmed on temporary and permanent pacing systems. All pacing practitioners,

and this includes physicians who implant temporary systems, should be familiar with programming the mode, rate, pacing output and sensitivity of a pacing system. In addition, they should also be able to diagnose and troubleshoot basic pacing problems like undersensing and oversensing. If dual-chamber pacing systems are used, programming the AV delay should be performed to optimise cardiac output and cardiac function (using echocardiographic guidance). Programming permanent pacing systems is more complicated than for temporary systems and should be performed only by individuals qualified to do so.

### TROUBLESHOOTING

The incidence of pacing system malfunction is difficult to determine due to inconsistent definitions and the lack of any comprehensive reporting mechanism or registry.<sup>39</sup> The malfunctions discussed here will be limited to those that are manifest on an electrocardiogram rhythm strip.

#### 1. Pacing stimuli present with loss of capture

Loss of capture is the failure of the pacemaker stimulus to produce electrical activation of the heart and a subsequent cardiac contraction. The diagnosis of loss of capture is based upon the presence of a pacing stimulus, without a subsequent P wave or QRS complex ([Fig. 32.9](#)). The result can be asystole or bradycardia, depending on the patient's underlying rhythm.

**Causes:** increase in pacing threshold above programmed value; lead dislodgement or malposition;

- pharmacological management of, 913
  - physiological variables in, 909
  - primary, 908
  - secondary, 908
  - treatment of, 905
  - types of blunt, 908, 909f
  - ventilation of, 912
  - Traumatic brain injury (TBI)
    - in blast victims, 1197
    - cerebral microdialysis in, 777, 778
    - neuromonitoring in, 772
    - brain tissue oxygen, 775
    - PbtO<sub>2</sub> readings, 775–777
    - paediatric, 1096
  - Traumatic events, 41
  - Traumatic phrenic nerve palsy, 929
  - Traumatic subarachnoid haemorrhage, 909
  - Trepostinil, 396
  - Tricuspid annular plane systolic excursion (TAPSE), 222, 381
  - Tricuspid regurgitation, 405, 1335
  - Tricyclic antidepressants, 805
    - overdose, 1140
    - poisoning, antidotes to, 1115t–1118t
  - Triggered activity, 304
  - Triiodothyronine, 136
  - Trimethoprim-sulfamethoxazole, 1293
  - Trimethoprim-sulphamethoxazole, 175
  - Troponin, of pulmonary embolism, 557
  - True shunt, 435
  - Tuberculomas, 173–174
  - Tuberculosis, 591–592, 599
    - diagnosis, 174
    - drug susceptibility tests, 174
    - GeneXpert MTB/RIF Ultra assay test, 174
    - nucleic acid amplification tests, 174
  - drug resistant, 174
    - extensively, 174
    - multidrug resistant, 174
  - epidemiology, 172
  - guidelines for diagnosis, 172
  - in HIV patients, 602
  - manifestations of, 173
  - with other clinical emergencies, 174
  - pathogenesis, 172, 173
  - pleural, 173
  - pulmonary, 173
  - risk factors for, 592t
  - treatment, 174
  - Tuberculous meningitis, 173, 761, 768
  - Tularaemia, 1208
  - Tumour lysis syndrome, 986, 1294
  - Tumour necrosis factor alpha, 797
  - Tumours
    - anthracycline cardiomyopathy, 984
    - bleomycin-related lung injury, 982
    - chemotherapy-induced toxicities, 983t
    - chemotherapy in ICU, 987
    - in children, 1043
    - definition of, 982
    - effect of critical care on cancer, 987
    - 5-fluorouracil cardiotoxicity, 984
    - ifosfamide neurotoxicity, 982
    - immune checkpoint inhibitors and, 984
    - immunotherapy, 984, 984t
    - monoclonal antibodies and, 985
    - oncological emergencies, 985
    - cardiac tamponade, 985
    - electrolyte disorders, 985
    - malignant pleural effusions, 987
    - spinal-cord compression, 985
    - superior mediastinal syndrome, 986
    - superior vena cava compression, 986
    - oncological therapy for, 988
    - outcomes of, 987
    - quality of life and long-term outcomes, 988
    - radiotherapy for, 985
    - solid, for intensive care unit, implications of, 982
    - treatments, 982
  - Twin study, 143
  - Type A Wolff–Parkinson–White syndrome, with positive R-waves, 327f
  - Type B Wolff–Parkinson–White syndrome, with negative QRS deflection, 327f
  - ‘Typical’ Afl waves, 316–317
- U
- Ultrasonography
    - for abdominal injury, 947
    - in acute pancreatitis, 643–644
  - Ultrasound physics, 219
    - comprehensive, 220, 221t
    - point-of-care, 220, 221t
  - Unconscious patient
    - clinical assessment of, 715
    - initial management of, 723
  - Undergoing neoadjuvant chemoradiotherapy, and physical exercise, 859
  - Unfractionated heparin (UFH), 560, 561
  - Unifocal atrial tachycardia, 314f, 314, 315f
  - Unresponsive coma, determination of death and, 112
  - Unstable angina, 263
    - clopidogrel in, 279
    - history and examination findings, 266t
    - management of, 283
  - Unstable patient, management of, abdominal injury, 948
  - Upper airway collapsibility, 968
  - Upper airway obstruction, 477, 478f
    - causes of, 477–478
    - in children, 1027
    - aetiology of, 1029
    - anaesthesia for, 1033
    - anatomical and developmental considerations for, 1027
    - care of secured airway in, 1033
    - causes of, 1029b
    - clinical presentation of, 1028
    - congenital, 1032
    - infections and, 1029
    - needle cricothyroidotomy for, 1034
    - pathophysiology of, 1028
    - subglottic stenosis and, 1032
    - tracheostomy for, 1034
    - trauma and, 1031
    - recognition of, 478
  - Upper gastrointestinal bleeding, 630. *See also* Lower gastrointestinal bleeding
    - angiography and angioembolisation, 633–634
    - clinical presentation of, 631
    - endoscopic haemostasis, 632–633
    - endoscopic treatments, 632
    - combinations, 633
    - endoscopic clipping, 633
    - endoscopic injection of adrenaline, 633
    - repeat endoscopy, 633
    - use of direct pressure and heat energy, 633
  - high-risk lesions, 632–633
  - pharmacological treatment, 632
  - prevention of rebleeding
    - acid suppression therapy, 634
    - eradication of *H. pylori*, 634–635
    - reduction in NSAID gastrotoxicity, 634
    - tranexamic acid, 634
  - risk assessment, 631
    - Blatchford Risk Score, 632, 632t
    - Rockall Score, 631t
    - of serious adverse events, 631
  - surgery, 634f, 634